Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.46 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.45 |
| ▸ | FABP7 | O15540 | 2/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | CASP3 | P42574 | 1/20 | 0.39 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12665926 | 1.00 | KMT2A (0.46) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL14656652 | 0.92 | KMT2A (0.47) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL13068845 | 0.89 | KMT2A (0.46) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL30388171 | 0.88 | KMT2A (0.41) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL5031702 | 0.87 | KMT2A (0.51) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL29776411 | 0.87 | KMT2A (0.45) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL29989813 | 0.86 | KMT2A (0.55) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL7853751 | 0.86 | KMT2A (0.55) | KMT2AFABP5FABP7EPHX2CASP3 | |
| SCHEMBL20371103 | 0.85 | KMT2A (0.48) | KMT2AFABP5FABP7EPHX2CA1 | |
| SCHEMBL13359306 | 0.85 | BCHE (0.48) | KMT2AFABP5FABP7EPHX2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12497460-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2025-12-16 | — | — | US | disclosed |
| US-20230285581-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2023-09-14 | — | — | US | disclosed |
| US-11666658-B2 | Rifamycin analogs and antibody-drug conjugates thereof | Regeneran Pharmaceuticals, Inc. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20230079407-A1 | ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF | REGENERON PHARMACEUTICALS, INC. | 2023-03-16 | — | — | US | disclosed |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | REGENERON PHARMACEUTICALS, INC. (US) | 2022-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230079407-A1 | ANTI-MSR1 ANTIBODIES AND METHODS OF USE THEREOF | CD47, MSR1, LDLR | KMT2A 710/4885FABP5 419/4885FABP7 396/4885 |
| US-11666658-B2 | Rifamycin analogs and antibody-drug conjugates thereof | ASGR1, CUTA, SRPRA | KMT2A 2098/4885FABP5 1960/4885FABP7 2344/4885 |
| US-12497460-B2 | Anti-MSR1 antibodies and methods of use thereof | CD47, MSR1, LDLR | KMT2A 710/4885FABP5 419/4885FABP7 396/4885 |
| US-20230285581-A1 | RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF | ASGR1, CUTA, SRPRA | KMT2A 2098/4885FABP5 1960/4885FABP7 2344/4885 |
| US-11377502-B2 | Anti-MSR1 antibodies and methods of use thereof | CD47, MSR1, LDLR | KMT2A 710/4885FABP5 419/4885FABP7 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.